Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

Investigate safety/tolerability after a single dose intranasal administration of AZD8848 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• History of birch and/or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years

• Body mass index (BMI) between 19 and 30 kg/ m2 and a weight between 50 and 100 kg

• No clinically relevant abnormal findings

Exclusion Criteria:

• Acute illness which requires medical intervention

• Definite or suspected personal history of adverse drug reactions or drug hypersensitivity

• Clinical relevant disease or disorder (past or present)

• A history of asthma